NCT06804135Recruiting
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer (STIRR Cervix Study)
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 27 Jan 2025
- Start date
- 25 Oct 2025
- Primary completion date
- 1 Jan 2029
- Lead sponsor
- Tata Memorial Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT06804135
What you commit to
- Study type: Observational
- Planned participants: 110
- From 25 Oct 2025 to the primary completion date, 1 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who will receive immune checkpoint inhibition (ICI) therapy.
Other illness
- Severe medical condition impairing complete treatment delivery.
- Patients with immunocompromised states or active infection.
- Patients on immunosuppressive drugs for other medical conditions.
Who the study is looking for
- Common Inclusion Criteria:
- Age 18 years and above.
- Ability to tolerate full course of pelvic radiotherapy+/- chemotherapy +/- brachytherapy.
- Ability to understand and willingness to sign an informed consent document.
- Should be willing to undergo extra biopsies and blood samples collection for translational research study.
- Cohort A:
- Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.
- Stage IIIB-IVA where palliative RT is indicated for palliative cohort.
- No previous irradiation to the pelvis or chemo therapy.
- Cohort B:
- Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.
- No previous irradiation to the pelvis or chemotherapy.
- Cohort C:
- Patients diagnosed with gynecological cancer and presenting with need of infield radiation.
- Planned for reirradiation.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tata Memorial Centre Coordinator of this site? Confirm its status | Mumbai | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.